Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20047146 | 0.91 | HDAC6 (0.57) | HDAC6PTGS2NAMPTESR2MEN1 | |
| SCHEMBL20047145 | 0.89 | HDAC6 (0.49) | HDAC6ESR2MEN1KMT2AAKR1C3 | |
| SCHEMBL26211248 | 0.86 | PKM (0.52) | PTGS2ESR2MEN1KMT2AAKR1C3 | |
| SCHEMBL20047121 | 0.85 | KMT2A (0.54) | PTGS2ESR2MEN1KMT2AAKR1C3 | |
| SCHEMBL20046995 | 0.83 | CYP11B1 (0.47) | HDAC6ESR2AKR1C3HDAC1CYP11B1 | |
| SCHEMBL20046992 | 0.81 | HDAC6 (0.69) | HDAC6NAMPTESR2MEN1KMT2A | |
| SCHEMBL20047170 | 0.81 | HDAC6 (0.49) | HDAC6NAMPTESR2MEN1KMT2A | |
| SCHEMBL20047016 | 0.78 | L3MBTL1 (0.46) | ESR2MEN1KMT2AAKR1C3PKM | |
| SCHEMBL31022086 | 0.78 | HDAC6 (0.47) | HDAC6NAMPTESR2MEN1KMT2A | |
| SCHEMBL26211247 | 0.77 | AKR1C3 (0.55) | ESR2MEN1KMT2AAKR1C3PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20200308135-A1 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | SAINT LOUIS UNIVERSITY (US) | 2020-10-01 | — | — | US | disclosed |
| WO-2017223514-A9 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | SAINT LOUIS UNIVERSITY (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308135-A1 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | NR1H2, NR1H3, PPARD | HDAC6 2050/4885PTGS2 1760/4885NAMPT 1542/4885 |
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | NR1H2, NR1H3, PPARD | HDAC6 2050/4885PTGS2 1760/4885NAMPT 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.